Buxin Chen

Title: Buxin Chen: Innovator in Antibody Therapeutics

Introduction

Buxin Chen is a prominent inventor based in San Marcos, CA (US). He has made significant contributions to the field of antibody therapeutics, holding a total of three patents. His work focuses on innovative solutions for treating disorders related to iron metabolism and complement-mediated disorders.

Latest Patents

Buxin Chen's latest patents include groundbreaking developments in antibody technology. One of his notable patents is for "Anti-TMPRSS6 antibodies and uses thereof." This patent describes antibodies and antigen-binding fragments that target type II transmembrane serine protease 6 (TMPRSS6) on cell surfaces, enhancing hepcidin expression. This innovation presents methods for treating disorders of iron metabolism using these anti-TMPRSS6 antibodies and fragments. Another significant patent is for "Anti-C1s antibodies and uses thereof." This patent outlines antibodies and antigen-binding fragments that bind to C1s, inhibiting its activity and modulating components in the classical pathway of complement activation. This invention provides methods for treating complement-mediated disorders using anti-C1s antibodies and fragments.

Career Highlights

Buxin Chen is currently associated with Mabwell Therapeutics, Inc., where he continues to advance his research and development in antibody therapeutics. His expertise and innovative approach have positioned him as a key figure in the field.

Collaborations

Buxin Chen collaborates with talented individuals such as Xin Du and Yu Jean Wang. Their combined efforts contribute to the advancement of therapeutic solutions in the biomedical field.

Conclusion

Buxin Chen's work exemplifies the spirit of innovation in the realm of antibody therapeutics. His patents and collaborations reflect a commitment to addressing critical health challenges through scientific advancements.